CHEMOTHERAPEUTIC SUPPRESSION OF IMMUNE ENHANCEMENT: A PRIMARY DETERMINANT OF SUCCESSFUL CANCER THERAPY
- 19 May 1973
- journal article
- Published by Elsevier in The Lancet
- Vol. 301 (7812) , 1092-1094
- https://doi.org/10.1016/s0140-6736(73)90399-1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- QUANTITATIVE EFFECTS OF NUTRITIONAL ESSENTIAL AMINO ACID DEFICIENCY UPON IMMUNE RESPONSES TO TUMORS IN MICEThe Journal of Experimental Medicine, 1973
- Inhibitory effects of BCG on adenovirus tumorigenesis: Dependence on administration scheduleInternational Journal of Cancer, 1972
- Serum‐mediated blocking of cell‐mediated anti‐tumor immunity in a melanoma patient: Association with BCG immunotherapy and clinical deteriorationInternational Journal of Cancer, 1972
- Bone Marrow: The Bursa Equivalent in Man?Science, 1972
- Immunity and tolerance: A unified conceptCellular Immunology, 1971
- IMMUNOSURVEILLANCE AND CANCERThe Lancet, 1970
- Immunity to malignant disease in man.BMJ, 1969
- DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUESThe Journal of Experimental Medicine, 1965
- Antigenic Properties of Other Experimental TumorsCold Spring Harbor Symposia on Quantitative Biology, 1961
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948